Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Sep;65(5):413–422. doi: 10.1016/j.curtheres.2004.10.002

Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study

Claudia Sama 1,*, Antonio Maria Morselli-Labate 1, Paolo Pianta 1, Laura Lambertini 1, Sonia Berardi 1, Gabriella Martini 1
PMCID: PMC3964524  PMID: 24672094

Abstract

Background:

Hepatic encephalopathy (HE) is a metabolic-neurophysiologicsyndrome that occurs in patients with advanced hepatic disease. One of the main pathogenic mechanisms is represented by circulating toxins produced by the intestinal metabolism of nitrogenous compounds. The therapeutic approach to HE is mainly based on drugs that eliminate ammonia-producing bacteria.

Objectives:

The aim of this study was to evaluate the effects of the nonabsorbable antibiotic rifaximin in patients with HE who were intolerant or nonresponsive to treatment with an oral, nonabsorbable disaccharide (lactulose).

Methods:

This uncontrolled, open-label, pilot study was conducted at the University of Bologna, Bologna, Italy. Patients aged ≥ 18 years with histologically proven liver cirrhosis and HE were studied. All patients were intolerant or nonresponsive to previous treatment with lactulose. Rifaximin tablets were administered to patients at a dosage of 400 mg TID for 10 days. The portal systemic encephalopathy (PSE) index was evaluated at enrollment and at the end of the treatment period. Tolerability was assessed using hematology, biochemistry, and urinalysis and by recording adverse effects (AEs). Results: Twenty-six patients (18 men, 8 women; mean [SD] age, 55.8 [8.0] years) were enrolled (intolerants, n = 17; nonresponders, n = 9). All patients completed the study. Significant improvement was shown in most of the 5 components of the PSE index after rifaximin administration in both intolerants and nonresponders. At the end of the 10-day treatment period, the PSE index was significantly reduced in both intolerants and nonresponders. Rifaximin was well tolerated; no clinically relevant AEs were observed during the treatment period. Conclusions: This pilot study of patients with liver cirrhosis and HE who were intolerant or nonresponsive to previous treatment with an oral, nonabsorbable disaccharide suggests that treatment with rifaximin may be considered as an adjuvant or an alternative treatment in reducing HE.

Keywords: hepatic encephalopathy, drug therapy, disaccharides, antibiotics, rifaximin, liver cirrhosis

Full Text

The Full Text of this article is available as a PDF (438.1 KB).

References

  • 1.Zieve L. The mechanism of hepatic coma. Hepatology. 1981;1:360–365. doi: 10.1002/hep.1840010414. [DOI] [PubMed] [Google Scholar]
  • 2.Capocaccia L., Ferenci P., Fischer J.E., Opolon P. Mechanisms of hepatic encephalopathy. Gastroenterol Int. 1989;2:131–140. [Google Scholar]
  • 3.Uribe M., Campollo O., Vargas F. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double blind, randomized clinical trial. Hepatology. 1987;7:639–643. doi: 10.1002/hep.1840070404. [DOI] [PubMed] [Google Scholar]
  • 4.Conn H.O. Adverse reactions and side effects of lactulose and related agents. In: Conn H.O., Bircher J., editors. Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates. Medi-Ed Press;; East Lansing, Mich: 1988. pp. 199–209. [Google Scholar]
  • 5.Tarao K., Ikeda T., Hayashi K. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut. 1990;31:702–706. doi: 10.1136/gut.31.6.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gillis J.C., Brodgen R.N. Rifaximin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467–484. doi: 10.2165/00003495-199549030-00009. [DOI] [PubMed] [Google Scholar]
  • 7.Conn H.O., Leevy C.M., Vlahcevic Z.R. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573–583. [PubMed] [Google Scholar]
  • 8.Connor B.A., Landzberg B.R. Prevention and treatment of acute traveler's diarrhea. Infect Med. 2004;21:18–19. [Google Scholar]
  • 9.Ericsson C.D. Travellers' diarrhoea. Int J Antimicrob Agents. 2003;21:116–124. doi: 10.1016/s0924-8579(02)00282-0. [DOI] [PubMed] [Google Scholar]
  • 10.Siegel S. McGrawHill; New York, NY: 1965. Non Parameerc Statistics for the Behavioral Sciences. [Google Scholar]
  • 11.Jalan R., Seery J.P., Taylor-Robinson S.D. Review article: Pathogenesis and treatment of chronic hepatic encephalopathy. Aliment Pharmacol Ther. 1996;10:681–697. doi: 10.1046/j.1365-2036.1996.58200000.x. [DOI] [PubMed] [Google Scholar]
  • 12.Als-Nilsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials. BMJ. 2004;328:1046–1050. doi: 10.1136/bmj.38048.506134.EE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Riordan S.M., Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–479. doi: 10.1056/NEJM199708143370707. [DOI] [PubMed] [Google Scholar]
  • 14.Blei A.T., Cordoba J., Practice Parameters Committee of the American College of Gastroenterology Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976. doi: 10.1111/j.1572-0241.2001.03964.x. for the. [DOI] [PubMed] [Google Scholar]
  • 15.Gerber T., Schomerus H. Hepatic encephalopathy in liver cirrhosis: Pathogenesis, diagnosis and management. Drugs. 2000;60:1353–1370. doi: 10.2165/00003495-200060060-00008. [DOI] [PubMed] [Google Scholar]
  • 16.Berk D.P., Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med. 1970;73:393–396. doi: 10.7326/0003-4819-73-3-393. [DOI] [PubMed] [Google Scholar]
  • 17.Morgan M.H., Read A.F., Speller D.C. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982;23:1–7. doi: 10.1136/gut.23.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pedretti G., Calzetti C., Missale G., Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A doubleblind, randomized trial. Ital J Gastroenterol. 1991;23:175–178. [PubMed] [Google Scholar]
  • 19.Parini P., Cipolla A., Ronchi M. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res Clin Exp. 1992;52:34–39. [Google Scholar]
  • 20.Bucci L., Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepaticencephalopathy. Curr Med Res Opin. 1993;13:109–118. doi: 10.1185/03007999309111539. [DOI] [PubMed] [Google Scholar]
  • 21.Zeneroli M.L., Venturini I., Stefanelli S. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol Res. 1997;35:557–560. doi: 10.1006/phrs.1997.0198. [DOI] [PubMed] [Google Scholar]
  • 22.Miglio F., Valpiani D., Rossellini S.R., Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997;13:593–601. doi: 10.1185/03007999709113333. [DOI] [PubMed] [Google Scholar]
  • 23.Williams R., James O.F., Warnes T.W., Morgan M.Y. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomised, dose-findingmulti-centre study. Eur J Gastroenterol Hepatol. 2000;12:203–208. doi: 10.1097/00042737-200012020-00012. [DOI] [PubMed] [Google Scholar]
  • 24.Festi D., Mazzella G., Orsini M. Rifaximin in the treatment of chronic hepatic encephalopathy: Results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp. 1993;54:598–609. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES